Skip To Main Content
Michael Rade on Muck Rack

Michael Rade

As seen in: Nature, BioRxiv, Cell Press, Cell Reports Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Michael Rade’s profile

Articles by Michael Rade

MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel - Leukemia

|
By Thomas C. Wiemers, Nora Grieb, Maximilian Ferle, Michael Rade, David Fandrei, Patrick Born, Luise Fischer, Song-Yau Wang, Sabine Seiffert, Anja Grahnert, Maik Friedrich, Ronny Baber, Markus Kreuz, Klaus H. Metzeler, Marco Herling, Carmen D. Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Andreas Boldt, Thomas Neumuth, Ulrike Kohl, Kristin Reiche, Tina Stegmann, Timm Denecke, Uwe Platzbecker, Hans-Jonas Meyer, Daniel Lavall, Maximilian Merz
| Nature Verified
To the Editor Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for relapsed and refractory multiple myeloma (RRMM), but its wider use has renewed attention to off-target toxicities.
Open in Who Shared Issue with article?

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma

|
By Michael Rade, David Fandrei, Markus Kreuz, Sabine Seiffert, Anja Grahnert, Maik Friedrich, Thomas C. Wiemers, Patrick Born, Luise Fischer, Heike Weidner, Lorenz C. Hofbauer, Ronny Baber, Song Wang, Enrica Bach, Sandra Hoffmann, Jonathan Scolnick, Mirco Friedrich, Farid Keramati, Peter Brazda, Zsolt Sebestyen, Jürgen Kuball, Miriam Alb, Lukas Scheller, Michael Hudecek, Hermann Einsele, Klaus H. Metzeler, Marco Herling, Carmen Diana Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Andreas Boldt, Ulrike Kohl, Uwe Platzbecker, Vladan Vucinic, Kristin Reiche, Maximilian Merz
| Cell Press Verified
Results We recruited a real-world cohort of 61 RRMM patients treated with BCMA-directed CAR T cells at our center. Samples of 57 patients were available for single-cell multi-omics profiling: A total of 135 peripheral blood mononuclear cell (PBMC) samples at 3 different time points were collected for single cell RNA, B cell receptor (BCR), TCR and surface protein profiling.
Open in Who Shared Issue with article?

ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice

|
By Justus Weber, Michael Rade, Peter Spieler, Claudia Müller, Charis Kalogirou, Laura Mainz, Jörg Lehmann, Robert Klopfleisch, Mathias Rosenfeldt, Sophia Danhof, K. Martin Kortüm, Ulrike Kohl, Hermann Einsele, Christoph Rader, Kristin Reiche, Thomas Nerreter, Michael Hudecek, Josefine Michael, Liz Therese Tony, Fabian Freitag
| Cell Reports Medicine Verified
Keywords receptor tyrosine kinase-like orphan receptor 2 ROR2 CAR T cell immunotherapy multiple myeloma clear cell renal cell carcinoma Introduction The receptor tyrosine kinase (RTK)-like orphan receptor 2 (ROR2) has been nominated as a target for RTK inhibitors due to its role in oncogenic signaling.1 ROR2 expression has been associated with cancer invasiveness and the formation of metastases,2,3,4 and several studies have suggested that ROR2 expression is a genetic disease and prognostic...
Open in Who Shared Issue with article?

Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

|
By David Fandrei, Sabine Seiffert, Universitätsklinikum Leipzig, Michael Rade
| tu-dresden.de
Abstract Externe IDs PubMedCentral PMC11707513 Schlagworte Humans, Multiple Myeloma/therapy, Antibodies, Bispecific/therapeutic use, Immunotherapy, Adoptive/methods, B-Cell Maturation Antigen/immunology, Middle Aged, Male, Female, Aged, Adult, Receptors, Chimeric Antigen/immunology, Neoplasm Recurrence, Local/therapy, T-Lymphocytes/immunology
Open in Who Shared Issue with article?

Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma - Nature Cancer

|
By Michael Rade, Song Wang, Sebastian Schwind, Georg-Nikolaus Franke, Uwe Platzbecker, Kristin Reiche
| Nature Verified
Abstract Markers that predict response and resistance to chimeric antigen receptor (CAR) T cells in relapsed/refractory multiple myeloma are currently missing. We subjected mononuclear cells isolated from peripheral blood and bone marrow before and after the application of approved B cell maturation antigen-directed CAR T cells to single-cell multiomic analyses to identify markers associated with resistance and early relapse.
Open in Who Shared Issue with article?

A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer

|
By Michael Rade, Markus Kreuz, Angelika Borkowetz, Ulrich Sommer
| tu-dresden.de
BACKGROUND: Clinical manifestation of prostate cancer (PCa) is highly variable. Aggressive tumors require radical treatment while clinically non-significant ones may be suitable for active surveillance. We previously developed the prognostic ProstaTrend RNA signature based on transcriptome-wide microarray and RNA-sequencing (RNA-Seq) analyses, primarily of prostatectomy specimens.
Open in Who Shared Issue with article?

A time-resolved meta-analysis of consensus gene expression profiles during human T-cell activation

|
By Vanessa Neuhaus, Michael Rade, Sebastian Boehlen, Dennis Loeffler
| BioRxiv
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Open in Who Shared View Duplicates (696) Issue with article?
Show More